Latest News and Press Releases

Recently announced topline results of Phase 3 ROMAN trial of avasopasem for radiotherapy-induced severe oral mucositis Enrollment ongoing in GRECO-1 and GRECO-2 trials of rucosopasem (GC4711) in...

Primary endpoint of reduction in incidence of severe oral mucositis (SOM) not met Trial demonstrated relative reduction in all key SOM endpoints, including more than halving the median...

MALVERN, Pa., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...

Event to be webcast on Thursday, September 23 at 11:00 a.m. ET Phase 3 ROMAN trial of avasopasem manganese, Galera’s lead candidate for SOM in patients with head and neck cancer, expected to read out...

Improvements observed in overall survival, progression-free survival, local tumor control, time to metastases, and tumor response rate Hazard ratios better than 0.5 on all survival and tumor outcome...

MALVERN, Pa., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...

Completed enrollment in pivotal Phase 3 ROMAN trial for severe oral mucositis (SOM) in patients with head and neck cancer; topline data expected in Q4 2021 Announced near doubling in median overall...

Topline data expected in the second half of 2021 Triggers $37.5M milestone payment from Blackstone Life Sciences MALVERN, Pa., June 28, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq:...

MALVERN, Pa., May 26, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...

Initiation builds on positive overall survival and tumor control data from Phase 1/2 trial Triggers $20M milestone payment from Blackstone Life Sciences 160-patient randomized, multicenter,...